HomeFOLD • NASDAQ
Amicus Therapeutics, Inc.
$11.78
After Hours:
$11.78
(0.00%)0.00
Closed: Mar 28, 4:30:00 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$11.86
Day range
$11.49 - $11.93
Year range
$9.70 - $14.57
Market cap
3.48B USD
Avg Volume
3.48M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
115.08M30.63%
Operating expense
107.45M-10.05%
Net income
-33.84M39.42%
Net profit margin
-29.4153.62%
Earnings per share
0.01105.26%
EBITDA
-1.51M96.17%
Effective tax rate
-6.90%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
286.20M-2.52%
Total assets
777.88M7.42%
Total liabilities
617.71M2.76%
Total equity
160.17M
Shares outstanding
295.38M
Price to book
21.56
Return on assets
-1.20%
Return on capital
-1.55%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-33.84M39.42%
Cash from operations
3.46M104.28%
Cash from investing
-23.96M64.08%
Cash from financing
8.21M1,373.97%
Net change in cash
-16.20M87.39%
Free cash flow
-7.47M88.93%
About
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates. Wikipedia
Founded
Feb 4, 2002
Employees
517
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu